Accès gratuit
Med Sci (Paris)
Volume 22, Numéro 4, Avril 2006
Page(s) 437 - 443
Section Recherche et partenariat
Publié en ligne 15 avril 2006
  1. Hamberg M, Svennsson J, Samuelson B. Thromboxanes : a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975; 72 : 2994–8. [Google Scholar]
  2. Vane JR, Flower R, Botting RM. The mechanism of action of aspirin. In : Vane JR, Botting RM, eds. Aspirin and other salicylates. London : Chapman and Hall Medical, 1992 : 35–59. [Google Scholar]
  3. Awtry EH, Loscalzo J. Aspirin. Circulation 2000; 101 : 1206–18. [Google Scholar]
  4. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors : structures, properties, and functions. Physiol Rev 1999; 79 : 1193–226. [Google Scholar]
  5. Halushka PV. Thromboxane A2 receptors : where have you gone ? Prostagl Lipid Med 2000; 60 : 175–89. [Google Scholar]
  6. Hirata M, Ushikubi F, Kakizuka A, et al. Two thromboxane A2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivities to Arg60 to Leu mutation. J Clin Invest 1996; 97 : 949–56. [Google Scholar]
  7. Kinsella BT. Thromboxane A2 signalling in humans : a "tail" of two receptors. Biochem Soc Trans 2001 : 29 : 641–54. [Google Scholar]
  8. Hall SE. Thromboxane A2 receptor antagonists. Med Res Rev 1991; 11 : 503–79. [Google Scholar]
  9. Dogné JM, Hanson J, de Leval X, et al. New developments on thromboxane modulators. Mini Rev Med Chem 2004; 4 : 649–57. [Google Scholar]
  10. Verbeuren TJ, Simonet S, Descombes JJ, et al. S 18204 : a new powerful TXA2-receptor antagonist with a long duration of action. Thromb Haemost 1995; 73 : 1324. [Google Scholar]
  11. Cimetière B, Dubuffet T, Muller O, et al. Synthesis and biological evaluation of new tetrahydronaphthalene derivatives as thromboxane receptor antagonists. Bioorg Med Chem Lett 1998; 8 : 1375–80. [Google Scholar]
  12. Verbeuren TJ, Vallez MO, Petit C, et al. Amelioration of albuminuria in the diabetic rat by S 18204, an anti-thromboxane receptor antagonist. Circulation 1995; 92 : 222. [Google Scholar]
  13. Simonet S, Descombes JJ, Vallez MO, et al. S 18886, a new thromboxane (TP)-receptor antagonist is the active isomer of S 18204 in all species, except in the guinea-pig. In : Sinzinger H et al., eds. Recent advances in prostaglandin, thromboxane and leukotriene research. New York : Plenum Press, 1998 : 173–6. [Google Scholar]
  14. Vallez MO, Rupin A, De Nanteuil G, Verbeuren T. Synergistic antithrombotic effects of the TP-receptor antagonist S 18886 and the direct thrombin inhibitor S 31307 in a thrombosis model of the rat abdominal aorta. Thromb Haemost 2001; P1625. [Google Scholar]
  15. Verbeuren T, Descombes JJ, Simonet S, et al. The TP-receptor antagonist S 18886 unmasks vascular relaxation and potentiates the anti-platelet action of PGD2. Thromb Haemost 1997; 693. [Google Scholar]
  16. Descombes JJ, Menant Y, Lavielle G, Verbeuren TJ. Binding properties of a potent, long acting new thromboxane receptor antagonist, [3H] S 18886, on human, rat and dog platelet membranes. Br J Pharmacol 1997; 122 : 381P. [Google Scholar]
  17. Gaussem P, Rény JL, Thalamas C, et al. The specific thromboxane receptor antagonist S 18886 : pharmacokinetic and pharmacodynamic studies. J Thromb Haemost 2005; 3 : 1437–45. [Google Scholar]
  18. Belhassen L, Pelle G, Dubois-Rande JL, Adnot S. Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin. J Am Coll Cardiol 2003; 41 : 1198–204. [Google Scholar]
  19. Taddei S, Virdis A, Ghiadoni L, et al. Endothelial dysfunction in hypertension. J Cardiovasc Pharmacol 2001; 38 : S11–4. [Google Scholar]
  20. Yang D, Félétou M, Levens N, et al. A diffusible substance(s) mediates endothelium-dependent contractions in the aorta of SHR. Hypertension 2003; 41 : 143–8. [Google Scholar]
  21. Maalej N, Osman HE, Shanmuganayagam D, et al. Antithrombotic properties of the thromboxane A2/prostaglandin H2 receptor antagonist S18886 on prevention of platelet-dependent cyclic flow reductions in dogs. J Cardiovasc Pharmacol 2005; 45 : 389–95. [Google Scholar]
  22. Osende JI, Shimbo D, Fuster V, et al. Antithrombotic effects of S 18886, a novel orally active thromboxane A2 receptor antagonist. J Thromb Haemost 2004; 2 : 492–8. [Google Scholar]
  23. Verbeuren TJ, Jordaens FH, Zonnekeyn LL, et al. Effect of hypercholesterolemia on vascular reactivity in the rabbit. I. Endothelium-dependent and endothelium-independent contractions and relaxations in isolated arteries of control and hypercholesterolemic rabbits. Circ Res 1986; 58 : 552–64. [Google Scholar]
  24. Verbeuren TJ. Endothelium and coronary atherosclerosis, an update. Coronary Artery Disease 1993; numéro spécial : 72–87. [Google Scholar]
  25. Cayatte AJ, Du Y, Oliver-Krasinski J, et al. The thromboxane-receptor antagonist, S 18886 but not aspirin inhibits atherogenesis in apolipoprotein E deficient mice : evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20 : 1724–8. [Google Scholar]
  26. Osborne JA, Lefer AM. Cardioprotective actions of thromboxane receptor antagonism in ischemic atherosclerotic rabbits. Am J Physiol 1988; 255 : H318–24. [Google Scholar]
  27. Van Diest M, Herman AG, Verbeuren TJ. Influence of hypercholesterolemia on the reactivity of isolated rabbit arteries to 15-lipoxygenase metabolites of arachidonic acid : comparison with platelet-derived agents and vasodilators. Prostaglandins Leukot Essent Fatty Acids 1996; 54 : 135–45. [Google Scholar]
  28. Montuschi P, Barnes PJ, Roberts LJII. Isoprostanes : markers and mediators of oxidative stress. FASEB J 2004; 18 : 1791–800. [Google Scholar]
  29. Ishizuka T, Suzuki K, Kawakami M, et al. Thromboxane A2 receptor blockade suppresses intercellular adhesion molecule-1 expression by stimulated vascular endothelial cells. Eur J Pharmacol 1996; 312 : 367–77. [Google Scholar]
  30. Kobayashi T, Tahara Y, Matsumoto M, et al. Roles of thromboxane A2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest 2004; 114 : 784–94. [Google Scholar]
  31. Zuccollo A, Shi C, Mastroani R, et al. The thromboxane A2 receptor antagonist, S 18886, prevents enhanced atherogenesis caused by diabetes mellitus. Circulation 2005; 112 : 3001–8. [Google Scholar]
  32. Ishizuka T, Matsui T, Kurita A. Ramatroban, a TP receptor antagonist, improves vascular responses to acetylcholine in hypercholesterolemic rabbits in vivo. Eur J Pharmacol 2003; 468 : 27–35. [Google Scholar]
  33. Egan KM, Wang M, Lucitt MB, et al. Cyclooxygenases, thromboxane, and atherosclerosis : plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 2005; 111 : 334–42. [Google Scholar]
  34. Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002; 296 : 539–41. [Google Scholar]
  35. Worth NF, Berry CL, Thomas AC, Campbell JH. S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits. Atherosclerosis 2005; 183 : 65–73. [Google Scholar]
  36. Viles-Gonzalez JF, Fuster V, Corti R, et al. Atherosclerosis regression and TP receptor inhibition : effect of S 18886 on plaque size and composition. A magnetic resonance imaging study. Eur Heart J 2005; 26 : 1557–61. [Google Scholar]
  37. Xu S, Maitland KA, Jiang B, et al. The thromboxane receptor antagonist S18886 attenuates renal oxidant stress and proteinuria in diabetic Apo E-deficient mice. Diabetes 2006; 55 : 110–9. [Google Scholar]
  38. Simmons TR, Cook JA, Moore JN, Halushka PV. Thromboxane A2 receptors in equine monocytes : identification of a new subclass of TXA2 receptors. J Leukoc Biol 1993; 53 : 173–8. [Google Scholar]
  39. Nagata T, Uehara Y, Numabe A, et al. Regulatory effect of thromboxane A2 on proliferation of vascular smooth muscle cells from rats. Am J Physiol 1992; 263 : H1331–8. [Google Scholar]
  40. Gao Y, Yokota R, Tang S, et al. Reversal of angiogenesis in vitro, induction of apoptosis, and inhibition of Akt phosphorylation in endothelial cells by thromboxane A2. Circ Res 2000; 87 : 739–45. [Google Scholar]
  41. Verbeuren TJ, Cohen RA. Role of TP-receptors in atherosclerosis and vascular endothelial dysfunction. In : Abstracts of the Symposium on endothelial factors and coronary disease. Hong Kong, China, 2004 : 22 (abstract). [Google Scholar]
  42. Tang M, Cyrus T, Yao Y, et al. Involvement of thromboxane receptor in the proatherogenic effect of isoprostane F2a-III. Evidence from apolipoprotein E- and LDL receptor-deficient mice. Circulation 2005; 112 : 2867–74. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.